These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 25646261)

  • 1. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
    Fernandez S; Thomas SJ; De La Barrera R; Im-Erbsin R; Jarman RG; Baras B; Toussaint JF; Mossman S; Innis BL; Schmidt A; Malice MP; Festraets P; Warter L; Putnak JR; Eckels KH
    Am J Trop Med Hyg; 2015 Apr; 92(4):698-708. PubMed ID: 25646261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines.
    Borges MB; Marchevsky RS; Carvalho Pereira R; da Silva Mendes Y; Almeida Mendes LG; Diniz-Mendes L; Cruz MA; Tahmaoui O; Baudart S; Freire M; Homma A; Schneider-Ohrum K; Vaughn DW; Vanloubbeeck Y; Lorin C; Malice MP; Caride E; Warter L
    PLoS Pathog; 2019 Apr; 15(4):e1007721. PubMed ID: 31009499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
    Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
    Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.
    Bischof GF; Magnani DM; Ricciardi M; Shin YC; Domingues A; Bailey VK; Gonzalez-Nieto L; Rakasz EG; Watkins DI; Desrosiers RC
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
    Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
    Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.
    Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT
    Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.
    Clements DE; Coller BA; Lieberman MM; Ogata S; Wang G; Harada KE; Putnak JR; Ivy JM; McDonell M; Bignami GS; Peters ID; Leung J; Weeks-Levy C; Nakano ET; Humphreys T
    Vaccine; 2010 Mar; 28(15):2705-15. PubMed ID: 20097152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.
    Lazo L; Izquierdo A; Suzarte E; Gil L; Valdés I; Marcos E; Álvarez M; Romero Y; Guzmán MG; Guillén G; Hermida Cruz L
    Microbiol Immunol; 2014 Apr; 58(4):219-26. PubMed ID: 24689365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.
    McBurney SP; Sunshine JE; Gabriel S; Huynh JP; Sutton WF; Fuller DH; Haigwood NL; Messer WB
    Vaccine; 2016 Jun; 34(30):3500-7. PubMed ID: 27085173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.
    Porter KR; Ewing D; Chen L; Wu SJ; Hayes CG; Ferrari M; Teneza-Mora N; Raviprakash K
    Vaccine; 2012 Jan; 30(2):336-41. PubMed ID: 22085548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
    Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
    Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys.
    Putnak R; Barvir DA; Burrous JM; Dubois DR; D'Andrea VM; Hoke CH; Sadoff JC; Eckels KH
    J Infect Dis; 1996 Dec; 174(6):1176-84. PubMed ID: 8940206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico.
    Diaz C; Lin L; Martinez LJ; Eckels KH; Campos M; Jarman RG; De La Barrera R; Lepine E; Toussaint JF; Febo I; Innis BL; Thomas SJ; Schmidt AC
    Am J Trop Med Hyg; 2018 May; 98(5):1435-1443. PubMed ID: 29512481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
    Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
    Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.
    Danko JR; Kochel T; Teneza-Mora N; Luke TC; Raviprakash K; Sun P; Simmons M; Moon JE; De La Barrera R; Martinez LJ; Thomas SJ; Kenney RT; Smith L; Porter KR
    Am J Trop Med Hyg; 2018 Mar; 98(3):849-856. PubMed ID: 29363446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.